

ASX Announcement

June 1, 2007

AMERICAN TESTS CONFIRM KEY PART OF INTELLIHEART PREDICTS HEART PROBLEMS BETTER

Scientific tests in the US have confirmed that the blood pressure component of IM Medical's cardiovascular diagnostic system can predict heart problems better than traditional blood pressure tests using a cuff on the arm.

The tests were done as part of the Strong Heart Study funded by the US National Institute of Health. Results will be published in the July 2007 edition of the American Heart Association journal *Hypertension*.

The Strong Heart Study used the SphygmoCor® system which measures central blood pressure without the need to insert an invasive catheter into the heart. The SphygmoCor® is unique as it is the only FDA approved and validated method to measure central blood pressure without invasion. The system was developed in Australia by AtCor Medical Holdings Limited (ASX: ACG). The system is used as part of IM Medical's *Intelliheart* diagnostic service which has been introduced in dozens of medical clinics in four States.

AtCor Medical announced this week that the US clinical data involved 3520 patients and demonstrated the importance of using central blood pressures to identify cardiovascular risk. Central blood pressure is the pressure at the heart whereas the pressure measured with a cuff on the arm can only estimate the central pressure and there can be big differences.

The Chief Executive Officer of AtCor Medical, Mr Duncan Ross, said the US tests showed that central blood pressure using SphygmoCor® was more strongly predictive of cardiovascular events than brachia (cuff-measured) pulse pressures in subjects with and without pre-existing atherosclerosis.

The Chief Executive Officer of IM Medical, Mr Tommas Bonvino, said the tests were further confirmation that SphygmoCor® and *Intelliheart* were important new additions in the fight against Australia's number one killer.

"The main benefit is that *Intelliheart* using SphygmoCor® can be done in the doctor's surgery in 40 minutes without the need for expensive and invasive equipment," Mr Bonvino said.

Further Information: IM Medical : Tommas Bonvino CEO (03) 9860 0900
Media enquiries : Michael Smith 0411 055 306